The ALS Center

James B. Caress, MD Professor of Neurology Director, ALS Center

Michael S. Cartwright, MD Associate Professor of Neurology

Carolanne Milligan, PhD Professor of Neurobiology Director, ALS Translational Science Unit

Theresa Johnston-Crews, RN, BSN, MBA Clinical Studies RN

Teresa Wilmoth Clinic Coordinator

Mozhdeh Marandi, MD Research Coordinator

Jeffrey B. Feldman, PhD Clinical Psychologist

Paul Eklund Assistive Technologist

Katherine Conrad, MSW Social Worker

Karen Downes, MEd/CCC Speech-Language Pathologist

Kate Phillips, MOT Occupational Therapist

Connie Paladenech, RRT Respiratory Therapist

Tony Walker, RRT Respiratory Therapist

Michelle Reeder, PT Physical Therapist

Monica Moorefield, RD Clinical Dietitian

Debbie Hicks Clinical Dictitian

Suzanne Gilroy ALS Association Jim "Catfish" Hunter Chapter Patient Services

Memorandum

TO:

Robert and Mary Ann Blais

The Blazeman Foundation for ALS MA, Inc.

FROM:

James B. Caress, MD

DATE:

April 14, 2015

This memo will serve to provide confirmation you that Wake Forest Baptist Health's ALS Center intends to continue our partnership with the Blazeman Foundation and will provide another year of funding for the HSP70 project in Dr. Carol Milligan's lab. In total, we have agreed to invest \$75,000 over three years into this effort. The Blazeman Foundation has contributed \$248,814 over the three years. The third year of funding is critical for the project to proceed. Dr. Milligan's lab will be completing the dose response trial in mice and developing a reliable detection assay for the HSP70 protein. Once that optimal dose is determined, this dose will be studied in an independently conducted trial of HSP70 in the ALS mouse model. These studies will provide essential pre-clinical results that will be part of our application to move forward to patient studies. With positive results in hand, it is my intent to apply for an IND with the USFDA and develop a first time in human study of this protein.

We are tremendously excited about this opportunity and hope for a good outcome. Importantly, we are so very grateful for your ongoing support of this project. While Wake Forrest School of Medicine is the only medical center engaged in researching this potential ALS treatment, the project would not be progressing if it were not for the partnership of the Blazeman Foundation. I want to reaffirm the ALS Center's partnership with the Blazeman Foundation will continue as we move forward. Should this approach be successful in ALS, we recognize, and will acknowledge in any reports, applications, or press releases that the approach and success was made possible because of the Blazeman Foundation's partnership with Wake Forest Health Sciences and our ALS Center.